JMP Securities analyst Konstantinos Aprilakis reiterated a Buy rating on Compugen Ltd (NASDAQ: CGEN) on September 20 and set a price target of $11. The company’s shares closed on Friday at $3.95.
According to TipRanks.com, Aprilakis has 0 stars on 0-5 star ranking scale with an average return of -11.2% and a 28.6% success rate. Aprilakis covers the Healthcare sector, focusing on stocks such as Erytech Pharma SA, Alnylam Pharma, and AnaptysBio Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Compugen Ltd with a $10 average price target.
See today’s analyst top recommended stocks >>
Based on Compugen Ltd’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $10.19 million. In comparison, last year the company had a GAAP net loss of $9.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases.
